Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female at least 9 years of age and older.~2. Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).~3. Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.~4. Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20, but no more than 100.~5. Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 30, but no more than 150.~6. Subjects with 2 or fewer facial nodules~Exclusion Criteria:~1. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.~2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema.~3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.~4. Subjects with a facial beard or mustache that could interfere with the study assessments.~5. Subjects with more than 2 facial nodules.~6. Evidence or history of cosmetic-related acne.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- IDP-126 Gel (Type: EXPERIMENTAL): Gel
- IDP-126 Component A (Type: ACTIVE_COMPARATOR): Component A
- IDP-126 Component B (Type: ACTIVE_COMPARATOR): Component B
- IDP-126 Component C (Type: ACTIVE_COMPARATOR): Component C
- IDP-126 Vehicle Gel (Type: PLACEBO_COMPARATOR): Vehicle Gel

Based on this trial design, predict the completion outcome and termination type (if applicable).